SystImmune

Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree
BioPharma Dive
Tue, 12/12/23 - 09:58 am
Bristol Myers Squibb
SystImmune
antibody-drug conjugate
cancer